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Millennium Institute, Sydney, AustraliaAbstractThe epidemiology of invasive fungal disease (IFD) due to ﬁlamentous fungi other than Aspergillus may be changing. We analysed clinical,
microbiological and outcome data in Australian patients to determine the predisposing factors and identify determinants of mortality.
Proven and probable non-Aspergillus mould infections (deﬁned according to modiﬁed European Organization for Research and Treatment
of Cancer/Mycoses Study Group criteria) from 2004 to 2012 were evaluated in a multicentre study. Variables associated with infection
and mortality were determined. Of 162 episodes of non-Aspergillus IFD, 145 (89.5%) were proven infections and 17 (10.5%) were
probable infections. The pathogens included 29 fungal species/species complexes; mucormycetes (45.7%) and Scedosporium species
(33.3%) were most common. The commonest comorbidities were haematological malignancies (HMs) (46.3%) diabetes mellitus (23.5%),
and chronic pulmonary disease (16%); antecedent trauma was present in 21% of cases. Twenty-ﬁve (15.4%) patients had no
immunocompromised status or comorbidity, and were more likely to have acquired infection following major trauma (p <0.01); 61
(37.7%) of cases affected patients without HMs or transplantation. Antifungal therapy was administered to 93.2% of patients (median 68
days, interquartile range 19–275), and adjunctive surgery was performed in 58.6%. The all-cause 90-day mortality was 44.4%; HMs and
intensive-care admission were the strongest predictors of death (both p <0.001). Survival varied by fungal group, with the risk of death
being signiﬁcantly lower in patients with dematiaceous mould infections than in patients with other non-Aspergillus mould infections. Non-
Aspergillus IFD affected diverse patient groups, including non-immunocompromised hosts and those outside traditional risk groups;
therefore, deﬁnitions of IFD in these patients are required. Given the high mortality, increased recognition of infections and accurate
identiﬁcation of the causative agent are required.
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M. Slavin and S. van Hal contributed equally to this workIntroductionThe frequency of invasive fungal disease (IFD) due to ﬁlamentous
fungi, or moulds, other than Aspergillus is increasing. Although
most infections have occurred in immunosuppressed patients,
immunocompetent hosts may be affected [1–5]. Recent reports
of infections following natural disasters [6] and case clusters
following iatrogenic inoculation [7,8] highlight the potential of
these environmental pathogens to cause serious infection in
healthy hosts. The epidemiology of IFD is changing. The fre-
quency of mucormycosis complicating diabetes mellitus has
increased, with the emergence of species such as Apophysomyces
elegans [9]. Scedosporium, including more recently designated
species [5], phaeohyphomycetes such as Verruconis gallopava
(previously Ochroconis gallopava) and the genus Rasamsonia
[10–14] have been reported in distinct regions or patient pop-
ulations. The intrinsic resistance of many non-Aspergillus moulds
to marketed antifungal agents is of concern [15].
Many case series or reviews of non-Aspergillus mould in-
fections have focused on speciﬁc patient populations, e.g. solid
organ transplant recipients, or particular infections, such as
phaeohyphomycosis, and have been limited by the lack, or
limited use, of molecular identiﬁcation techniques [1,3,4,10].
We performed this multicentre study of non-Aspergillus mould
infections in Australian tertiary hospitals to better understand
the current epidemiology, predisposing factors for and out-
comes of these infections.MethodsStudy design
A retrospective multicentre, observational study of non-
Aspergillus mould infections in adults from 2004 to 2012 was
conducted through the Australia and New Zealand Mycoses
Interest Group (ANZMIG). Human Research Ethics Commit-
tee approval was obtained at all study sites.
Data collection
Cases were identiﬁed through interrogation of microbiology
and pathology laboratory information systems, infectious dis-
eases databases, and hospital medical records, according to theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfInternational Statistical Classiﬁcation of Diseases and Related
Health Problems, 10th revision, Australian Modiﬁcation (ICD-
10-AM) for fungal disease and comorbidities [16]. Trained
personnel collected data on standardized clinical record forms.
Cases were reported to a central registry and reviewed by a
data review committee (S.C., M.S., S.v.H., T.C.S., and A.L.) to
determine the inclusion criteria for: (a) incident infection in
unique (separate) patients, and (ii) only proven or probable IFD
(see ‘Deﬁnitions’). Cases classiﬁed by the data review com-
mittee as ‘colonization’ or as possible IFD were excluded.
Data on patient demographics and comorbidities (e.g. malig-
nancy, transplantation, and diabetes mellitus), classic risk factors
for IFDs (e.g. immunosuppressive therapies and intensive-care
unit (ICU) stay) [2–5,9,17] and other possible predisposing
factors (e.g. major trauma), clinical manifestations, laboratory
and radiological results and antifungal and other therapies were
collected. Patients were followed for a period of 6 months
(180 days) from the time of IFD diagnosis or until death. Clinical
outcomes, including dates of death, were recorded.
Deﬁnitions
Deﬁnitions of proven or probable non-Aspergillus IFD were
adapted from the European Organization for Research and
Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
deﬁnitions for IFD [18]. IFD was proven when fungal elements
were visualized microscopically within tissue, or a mould was
cultured from a sterile site, for a patient with clinical and radio-
logical features of infection. A probable infection was deﬁned by
culture of a mould from a non-sterile site, including bron-
choalveolar lavage ﬂuid, in a patient with clinical and radiological
evidence of IFD; host-speciﬁc criteria were not required (in
contrast to the EORTC/MSG criteria for probable IFD [18]).
Infection was deﬁned as disseminated when two or more
non-contiguous sites were involved or blood cultures were
positive. Major trauma referred to signiﬁcant tissue injury
requiring surgical intervention. The primary clinical outcome
was assessed as 90-day all-cause mortality, in order to allow
comparison of outcomes with those of other studies [2,19].
Secondary outcomes included all-cause mortality at 30 days and
at the end of follow-up (180 days). Physician-ascribed attrib-
utable mortality was also assessed.
Microbiology
Cultures and histopathological specimens were examined at
participating sites. Fungi were identiﬁed with standard pheno-
typic methods. Ninety isolates (63.4%) were also subjected to
species conﬁrmation by DNA sequencing, 80 at one of two
reference mycology laboratories (Westmead Hospital, Sydney;
SA Pathology, Adelaide), with targeting of the internal tran-
scribed spacer regions or the D1/D2 regions of the 28S (largeectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 490.e1–490.e10
TABLE 1. Causative pathogens: non-Aspergillus mould
infections, Australia 2004–2012
Organism
No. of
isolates
No. identiﬁed
by DNA sequencing
490.e3 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIsubunit) of the rRNA gene [20,21]. In addition, the gene for the
translation elongation factor EF1α was sequenced for identiﬁ-
cation of Fusarium species [22].
When a fungus was visualized in tissue and other sterile site
specimens but not cultured, internal transcribed spacer
sequencing [23] was performed for identiﬁcation. When spe-
cies assignment could not be made, or when sequencing was
technically unsuccessful, isolates were categorized by genus
(e.g. Rhizopus) or class (e.g. agent of mucormycosis).
Statistical analysis
Associations between fungal species and patient comorbidity or
predisposing factors for non-Aspergillus IFDs were analysed.
Determinants of all-cause 90-day mortality for all infections,
and for subgroups of non-Aspergillus IFD (grouped by mucor-
mycete, Scedosporium, Fusarium and dematiaceous mould in-
fections) were also examined. Categorical variables were
compared by use of the chi-square test or Fisher’s exact test,
and continuous variables by the use of Student’s t-test or the
Mann–Whitney U-test. Multivariate backward stepwise logistic
regression analysis was performed to identify independent
predictors of disseminated infection and of mortality for the
entire study cohort and for subgroups of infection (as above).
Variables with a p-value of <0.20 by univariate analysis were
included in the model. Kaplan–Meier survival analysis was
performed for all-cause 90-day mortality. Calculations were
performed with SPSS version 22.0 (SPSS, Chicago, IL, USA).Mucormycetes 74 —
Apophysomyces species 4 3
Lichtheimia species 2 2
Mucor species 7 4Results
Rhizopus species 40 24
Rhizomucor species 4 4
Saksenaea species 4 3
Unclassiﬁed mucormycete 12a —
Scedosporium species 54 —
Scedosporium apiospermum/Pseudallescheria
boydii species complex
25b 10
S. proliﬁcans 29 5
Fusarium species 13 —
F. solani complex 7 4
F. oxysporum complex 1 1
Unclassiﬁed 5c 5
Other hyphomycete fungi 4 —
Phialemonium species 1 1
Paecilomyces species 3 3
Dematiaceous fungi 16 —
Acrophialophora species 1 —
Alternaria species 1 1
Bipolaris species 2 1
Chaetomium species 1 1
Cladophialophora species 1 1
Curvularia species 2 1
Exserohilum species 2 1
Exophiala species 1 —
Fonsacaea species 1 —
Microsphaeropsis species 1 1
Verruconis species 2 2
Phialophora species 1 1
Other 4d 2
aSee text for details.
bIncludes two cases of S. aurantiacum infection: one ocular infection resulting
in enucleation of the eye, and one case of cerebral abscess.
cIdentiﬁed as Fusarium species by DNA sequencing.
dGanoderma species, Lasiodiplodia species, Trichoderma longibrachiatum, and
Thermomyces lanuginosus.One hundred and eighty non-Aspergillus mould infections were
reported from 15 tertiary hospitals. All jurisdictions other than
Queensland and Tasmania were represented. There were no
case clusters. Following review, 162 of 180 episodes of infec-
tion (162 patients) met the inclusion criterion of proven or
probable IFD. There were 145 (89.5%) proven and 17 (10.5%)
probable infections. There was no trend in the annual fre-
quency of cases (range 12–24).
Causative fungi
Twenty episodes of infection were diagnosed by histopathology
alone. Of 142 culture-positive episodes, diagnosis was made by
culture alone in 76 (53.5%) and with tissue histopathology in 66
(46.5%). DNA sequencing was performed in 91 of 142 (64.1%)
culture-positive episodes and in ten (50%) histologically
conﬁrmed cases. In referred samples (n = 80), the ﬁnal identi-
ﬁcation was considered to be that obtained by the reference
laboratory, including those for which species identiﬁcation was
discordant (3.8% of cases; data not shown).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectOverall, 112 isolates (69.1%) were identiﬁed to species level
and 38 (23.5%) to genus level. The remaining 12 cases were all
attributed to mucormycetes following visualization of charac-
teristic hyphae on histopathology.
Infections were caused by a range of pathogens. Mucormy-
cetes accounted for 74 of 162 (45.7%) episodes, followed by
Scedosporium (33.3%); Fusarium species caused 8% of cases, and
there were four infections caused by very uncommon moulds
(Table 1). Three patients had mixed infections, one each due to
Fusarium and Paecilomyces, Fusarium and Mucor, and Exserohilum
and Scedosporium species.
Most mucormycetes (54%; Table 1) were from the genus
Rhizopus. Scedosporium proliﬁcans accounted for ~50% of Sce-
dosporium infections. Of ten phenotypic ‘Scedosporium apio-
spermum’ isolates, two were Scedosporium aurantiacum by DNA
sequencing; however, as not all Scedosporium isolates were
subjected to molecular identiﬁcation, isolates will hereafter be
referred to as ‘S. proliﬁcans’ or ‘S. apiospermum/Pseudallescheria
boydii species complex’. Dematiaceous fungi were diverse
(Table 1). The pattern of pathogens was similar across in-
stitutions, and was independent of location, with the exception
of environmental fungi (Ganoderma species and Lasiodiplodiaious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 490.e1–490.e10
TABLE 2. Patient comorbidities and predisposing factors in
162 episodes of non-Aspergillus mould infection
Characteristic No. of episodes (%)
No comorbidity or host immunocompromised status 25 (15.4)
Underlying comorbid conditions
Diabetes mellitus 38 (23.5)
Chronic obstructive pulmonary disease 26 (16)
Chronic renal failure 17 (10.5)
Rheumatological conditions 14 (8.6)
Haematological malignancya 75 (46.3)
Stem cell or bone marrow transplant 27 (16.7)
Solid organ transplant 23 (14.2)
Solid malignancy 7 (4.3)
Predisposing factors
Major or minor trauma within the preceding 30 days 34 (21)
Major surgery within the preceding 30 days 32 (19.8)
Hospital construction within the preceding 30 days 30 (18.5)
Cancer chemotherapy 69 (42.6)
Corticosteroids 88 (54.3)
Monoclonal antibodies 18 (11.1)
Calcineurin inhibitors 34 (21)
Neutropenia within the preceding 30 days 64 (39.5)
Other patient characteristics
Antifungal prophylaxis 64 (39.5)
Fluconazole 17 (11.1)
Itraconazole 7 (4.3)
Voriconazole 13 (8.0)
Posaconazole 20 (12.3)
Liposomal amphotericin B 3 (1.9)
Current smoker 37 (22.8)
Intensive-care unit admission at time of diagnosis
of fungal infection
59 (36.4)
aHaematological cancers included: acute leukaemia (n = 42), chronic leukaemia
(n = 8), lymphoma (n = 8), multiple myeloma (n = 4), myelodysplastic syndrome
(n = 8), and other cancers (n = 5).
CMI Slavin et al. Non-Aspergillus mould infections and outcomes 490.e4species) that caused post-inoculation injury infections in trop-
ical northern Australia.
Patient characteristics and comorbidities
The median age of patients was 57 years (interquartile range
(IQR) 45–65 years); 108 (66.7%) were male. Although infection
peaked in patients aged 60–70 years, the distribution of aetio-
logical fungi was similar across age groups (Fig. 1). The number
of cases varied by jurisdiction, reﬂecting the population density
and medical services at each institution (data not shown).
Patient comorbidities and predisposing factors for non-
Aspergillus mould infections are shown in Table 2. Of all in-
fections, 37.7% occurred in patients without haematological
malignancy (HM) cancers, haematopoietic stem cell trans-
plantation (HSCT), or solid organ transplantation (SOT). No
patient with diabetes mellitus (n = 38; 23.5%) had concurrent
ketoacidosis. Thirty-four patients (21%) had antecedent trau-
matic injuries. Over 50% of patients receiving antifungal pro-
phylaxis (39.5% of all patients) were taking voriconazole or
posaconazole. Twenty-ﬁve patients (15.4%) had neither under-
lying immunocompromised status nor comorbidity; they were
more likely than the remaining 137 to have acquired infection
through major trauma (8/25 (32%) vs. 8/137 (5.8%), p <0.01).
Comorbidity, predisposing factors, and causative
pathogens
The inﬂuence of clinical variables on IFD aetiology is shown
in Table 3. Diabetes mellitus as such did not select for a
mucoraceous infection. As compared with infections due to
non-mucormycetes (n = 88), there was an association betweenFIG. 1. Distribution of non-Aspergillus mould infection episodes ac-
cording to age and fungal genera.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infmucormycosis and voriconazole prophylaxis (13.5% (10/74) vs.
3.4% (3/88), p 0.022). As compared with non-Fusarium in-
fections (n = 149), cases of fusariosis (n = 13) were signiﬁcantly
more common in neutropenic patients (18.8% vs. 1%, p <0.001)
and HM patients (16% vs. 1.1%, p 0.001). Scedosporiosis
(n = 54) was more common post-SOT (52.2% (12/23) vs. 30.2%
(42/39), p 0.039) than in non-organ transplant recipients.
Site of infection
Sixty-one patients (37.7%) presented with disseminated infec-
tion, and 101 (62.3%) with localized infection. Diverse
anatomical sites were affected (Fig. 2), but, overall, the lung was
the most common (40.1%). Of 17 blood isolates, 14 were
S. proliﬁcans, two were Fusarium solani, and one was a mucor-
mycete. Four patients with HM/HSCT were diagnosed with
isolated fungaemia (all S. proliﬁcans). Eleven of 19 cases of brain
infection were caused by a mucormycete, and six by Scedo-
sporium species. All 15 eye infections manifested as endoph-
thalmitis (50% due to Scedosporium). The two known
S. aurantiacum infections presented as localized eye and brain
disease. Four cases of endocarditis complicated by culture-
positive endovascular infection were due to Thermomyces
lanuginosus (n = 1), mucormycetes (n = 2), and Trichoderma
longibrachiatum (n = 1).
The gastrointestinal tract, heart, liver and deep arterial
thrombi (Fig. 2) were involved only in disseminated infection,ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 490.e1–490.e10
TABLE 3. Non-Aspergillus mould pathogen (n [ 165 isolates) groups according to major patient co-morbidity and predisposing
factors
Variable Mucormycete (n [ 74) Scedosporium (n [ 54) Fusarium (n [ 13) Dematiaceous molds (n [ 16) Other (n [ 8)
Co-morbidity
None (n = 25)a 8 9 1 4 3b
Diabetes (n = 38) 20 13 1 4 1
Chronic lung disease (n = 26) 11 11 0 3 1
Hematologic malignancy (n = 75) 36 23 12c 5 1
Solid organ cancer (n = 7) 2 4 0 1 0
Stem cell transplant (n = 27) 13 9 3 3 0
Solid organ transplant (n = 23) 8 12c 0 3 1
Predisposing factor
Neutropenia (n = 64) 33 18 11c 3 1
Major or minor trauma (n = 33) 17 10 2 4 3d
Building construction (n = 30) 10 12 3 2 3
Medications prescribede
Antifungal prophylaxis
Any Agent (n = 64) 34 19 10 3 0
Voriconazole (n = 13) 10c 3 0 0 0
Posaconazole (n = 20) 10 7 4 0 0
Corticosteroids (n = 88) 40 29 10 8 4
Monoclonal antibody (n = 18) 7 7 3 1 1
aAlso no host immunocompromise.
bPaecilomyces, Trichoderma and Thermomyces species.
cSee text for association details.
dLasiodiplodia, Phialemonium, and Paecilomyces species.
eMedications prescribed within the preceding 30 days.
490.e5 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIwith the eye being the only other site associated with dissem-
inated disease (16.4% (10/61) of cases vs. 5.1% (5/101) of cases
not affecting the eye, p 0.02). Underlying HM independently
predicted disseminated infection (OR 2.7, 95% CI 1.4–5.3,
p 0.03; Table 4). Dematiaceous moulds were associated with
localized infections.
Patient management
Antifungal treatment was initiated in 151 patients (93.2%) and
continued for a median of 68 days (IQR 19–275 days); 114Body site involved 
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FIG. 2. Body site of infection in non-Aspergillus mould infections. Note
that all involved sites are depicted in patients with disseminated disease
(n = 61). Involvement of the liver, gastrointestinal tract, heart and deep
arterial thrombi was exclusively associated with disseminated infections,
as were bloodstream infections (by deﬁnition).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(74.5%) patients received monotherapy. Dual-agent and
three-agent antifungal therapy were used in 34 and three
patients, respectively. Antifungal therapy was largely deter-
mined by the fungal pathogen. Amphotericin B monotherapy
(predominantly liposomal amphotericin B) was typically used
to treat mucormycoses (67.6%; 60/74 cases), and vor-
iconazole alone (n = 29) or in combination with terbinaﬁne
(n = 13) was predominantly prescribed for Scedosporium in-
fections (77.8%; 42/54 cases).TABLE 4. Comparison of features of disseminated and
localized non-Aspergillus mould infections in 162 patients
Disseminated
infection
(n [ 61),
no. (%)
Localized
infection
(n [ 101),
no. (%) p
Comorbidities
None 8 (13.1) 17 (16.8) 0.66
Diabetes mellitus 15 (24.6) 23 (22.8) 0.79
Chronic lung disease 9 (14.8) 17 (16.8) 0.73
Haematological malignancy 38 (62.3) 37 (36.6) 0.002
Solid organ cancer 2 (3.3) 5 (5.0) 0.71
Stem cell transplant 14 (23.0) 13 (12.9) 0.095
Solid organ transplant 8 (13.1) 15 (14.9) 0.76
Predisposing factors
Neutropenia 34 (55.7) 30 (29.7) 0.001
Major or minor trauma 11 (18.0) 23 (22.8) 0.47
Building construction 10 (16.4) 10 (19.8) 0.68
Medications received
Cancer chemotherapy 35 (57.4) 34 (33.7) 0.003
Steroids 37 (60.7) 51 (50.5) 0.21
Monoclonal antibodies 10 (16.4) 8 (7.9) 0.10
Calcineurin inhibitors 13 (21.3) 21 (20.8) 0.94
Fungal pathogena
Mucormycete 29 (47.5) 45 (44.6) 0.71
Scedosporium 20 (32.8) 34 (33.7) 0.91
Fusarium 9 (14.8) 4 (4.0) 0.01
Dematiaceous mould 2 (3.3) 14 (13.9) 0.03
Other 2 (3.3) 6 (5.9) 0.71
aOne patient had disseminated infection due to a mucormycete and Fusarium.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 490.e1–490.e10
CMI Slavin et al. Non-Aspergillus mould infections and outcomes 490.e6Adjunctive surgery was performed in 95 of 162 (58.6%)
patients, and appeared to be determined by the site of infection
rather than the pathogen. Adjunctive granulocyte–macrophage
colony-stimulating factor or granulocyte infusion therapies
were used in only four haematology patients.
Outcomes
The all-cause 90-day mortality was 44.4% (72/162 patients),
with most (94.4%) deaths being attributable to IFD. Deaths
occurred at a median of 14 days (IQR 5–28 days) after IFD
diagnosis. All-cause 30-day and 180-day mortality were 35.8%
(n = 58) and 47% (n = 77), respectively. Table 5 shows the
variables associated with mortality by univariate and multivar-
iate analyses. Underlying HM and ICU admission (both p
<0.001) were the strongest independent predictors of outcome
(see also Figs. 3(a) and (b)), but rheumatological disease and
disseminated infection (both p 0.02) also increased the risk of
death. The type of haematological cancer and neutropenia did
not predict death. Surgery was associated with a survival
advantage on multivariate analysis (OR 0.34, 95% CI 0.13–0.88,
p 0.027).
Fungal type and outcome
Dematiaceous fungal infections were independently associated
with reduced mortality (OR 0.1, 95% CI 0.02–0.9, p 0.04)TABLE 5. Univariate and multivariate analysis of overall 90-day ou
Variable
Univariate analysis
Died (n [ 72) Alive (n [ 90)
Age (years), median (IQR) 58 (40–76) 56 (33–79)
Male gender, no. (%) 48 (66.7) 60 (66.7)
Current smoker, no. (%) 12 (16.7) 25 (27.8)
Comorbidities/predisposing conditions, no. (%)
Diabetes 12 (16.7) 26 (28.9)
COPD 12 (16.7) 14 (15.6)
Chronic renal failure 2 (2.8) 15 (16.7)
Rheumatological malignancy 10 (13.9) 4 (4.4)
Haematological malignancy 58 (77.3) 17 (18.9)
Bone marrow transplant 22 (30.6) 5 (5.6)
Solid organ transplant 5 (6.9) 18 (20.0)
Solid malignancy 3 (4.2) 4 (4.4)
No comorbidities 1 (1.4) 24 (26.7)
Additional predisposing factors within the preceding 30 days, no. (%)
Major trauma 4 (5.6) 12 (13.3)
Surgery 15 (20.8) 17 (18.9)
Hospital construction 13 (18.1) 17 (18.9)
Medications prescribed
Chemotherapy 47 (65.3) 22 (24.4)
Steroids 52 (72.2) 36 (40)
Monoclonal antibodies 15 (20.8) 3 (3.3)
Calcineurin inhibitors 13 (18.1) 21 (23.3)
Neutropenic 49 (68.1) 15 (16.7)
Manifestations of infection
Localized infection 30 (41.7) 70 (77.8)
Disseminated infection 42 (58.3) 20 (22.2)
Within ICU at the time of IFI 38 (52.8) 21 (23.3)
Fungal aetiology, no. (%)
Mucormycetes 38 (52.8) 36 (40.0)
Scedosporium species 25 (34.7) 28 (31.1)
Fusarium species 8 (11.1) 5 (5.6)
Dematiaceous mould 2 (2.8) 14 (15.6)
COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
aVariables that were included in the multivariate analysis but dropped out of the ﬁnal mode
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inf(Fig. 3(c)) in the multivariate analysis of the entire dataset.
When subgroup analysis examining mortality was performed
for the fungal groups with sufﬁcient numbers, namely the
mucormycetes, Scedosporium species, and dematiaceous
moulds, no fungal-speciﬁc risk factors for outcome that were
different from the entire dataset were identiﬁed on either
univariate or multivariate analysis. Speciﬁcally for mucormycte
infections, being in an ICU at diagnosis (OR 6.6, 95% CI
1.4–29), both a diagnosis of acute leukemia (OR 17.8, 95% CI
3–103) and a diagnosis of of haematological cancer other than
acute leukaemia (OR 29.5, 95% CI 4.5–196) and disseminated
infection (OR 4.9, 95% CI 1.2–20.2) were all independent
predictors of mortality.DiscussionThis multicentre study of non-Aspergillus ﬁlamentous fungal in-
fections describes the epidemiology of these emerging patho-
gens in the era of molecular diagnostics and contemporary
management protocols [24]. A broad range of fungi caused IFD.
Although many patients had traditional predisposing factors,
predominantly immunosuppression, >15% had no comorbid-
ities and were not immunocompromised, and 37.7% were not
undergoing treatment for HM or transplantation.tcome in patients with non-Aspergillus mould infections
Multivariate analysis
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FIG. 3. (a) Kaplan–Meier survival curve stratiﬁed by the presence or absence of an active haematological malignancy. (b) Kaplan–Meier survival curve
stratiﬁed by body site of infection: disseminated invasive fungal disease and different body sites of infection. (c) Kaplan–Meier survival curve stratiﬁed
by classiﬁcation of fungal genus.
490.e7 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIInclusion of multiple centres in this study enabled the
recognition of 29 aetiological species/species complexes;
because of the rarity of some species, results from single in-
stitutions or speciﬁc populations are unlikely to be represen-
tative. Mucormycetes were the leading cause of IFD (45.7%). As
expected, we observed mucormycosis in HSCT, SOT and dia-
betes patients [2,17,25,26]. Notably, mucoraceous fungi were
also the commonest causes of infection following various
antecedent traumas, supporting a recent observation linking
these infections to road trauma [27].
The epidemiology of non-Aspergillus moulds in this study
differed from that in other global reports. Outside of Australia,
Fusarium species are typically the second commonest non-
Aspergillus pathogens after the mucormycetes, generally
affecting haematology patients or SOT recipients [2,25,26,28].
Although fusariosis did occur in patients with HMs in our study,
these infections were uncommon (8%). In contrast, the
prominence of Scedosporium species (33.3%) reﬂects a relatively
high incidence of these infections in Australia [5,28,29] asClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcompared with other settings [2]. Chronic lung disease, SOT
and trauma have been observed to be predisposing factors for
scedosporiosis [3,5,30,31]. The reasons for these subtle dif-
ferences in epidemiology are unknown, but may reﬂect the
abundance of Scedosporium in the soil, especially in Australian
urban environments [32]. It is possible that engaging in major
horticulture/landscaping activities poses an added risk for
scedosporiosis.
Another key ﬁnding is the range of patient populations
affected outside those traditionally at high risk for IFD (i.e. HM
and SOT recipients). Emerging at-risk populations included
those with chronic lung disease, those with rheumatological
conditions (presumably due to the increasing use of immune-
modulating drugs such as tumour necrosis factor-α antago-
nists [33]), and those sustaining trauma. Indeed, inoculation
injuries caused 34 (21%) of all infections. Although mucormy-
cetes were common (51%), Scedosporium species and dema-
tiaceous and other environmental moulds were also isolated,
highlighting the pathogenic potential of these fungi after evenious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 490.e1–490.e10
CMI Slavin et al. Non-Aspergillus mould infections and outcomes 490.e8minor trauma. Notably, 15% of cases in our study were iden-
tiﬁed in patients without comorbidities or immunocompro-
mised status. In a previous study of mucormycosis, 19% of
patients had no apparent comorbidity [17]. It is of interest that
mucormycosis represented only half of the infections in diabetic
patients, suggesting that the epidemiology of non-Aspergillus
mould infections is changing in this patient group [19]. Although
voriconazole prophylaxis was associated with mucormycosis
[2,34], it may represent a surrogate for an alternative mucor-
mycosis risk factor rather than causation as such. However, our
study was not designed to resolve this important issue.
Dematiaceous fungal infections remain uncommon, but
appear to be emerging in a diverse group of patients, including
normal hosts after trauma. Two V. gallapova infections were
observed, both in neutropenic haematology patients with
adverse outcomes despite combination therapy with pos-
aconazole or voriconazole and amphotericin B, all of which
have, in general, good in vitro activity against V. gallopava [35].
Nonetheless, overall, dematiaceous moulds were associated
with lower mortality than other non-Aspergillus IFDs, which is
similar to recent ﬁndings of phaeomycotic infections in SOT
recipients (7% mortality), although most of these had skin
rather than disseminated infection [10]. In contrast, there was a
33% mortality rate in patients with proven/probable dematia-
ceous mould infections in a cancer centre, and dissemination
was identiﬁed as a risk for mortality [1]. These outcome dif-
ferences probably reﬂect variability in host immunosuppression
and site of infection.
As almost 40% of our cases occurred outside the haematology
and transplant patient population, there is a clear need to extend
deﬁnitions of non-Aspergillus mould IFD beyond these patient
cohorts. Although themajority of our cases (89.5%)were proven
infections, our assignment of probable IFD cases outside of
recognized high-risk groups was arbitrary, albeit based on
modiﬁed EORTC/MSG deﬁnitions [18], in that patients with
probable IFD did not have to meet prespeciﬁed host criteria.
Assignment of ‘possible’ IFD, especially in this group, was not
feasible. Two factors impact on the criteria for categorizing these
IFDs. The ﬁrst is the lack of accessible, rapid methods to detect
non-Aspergillusmoulds in bronchoalveolar lavage ﬂuid, blood, and
other specimens. The US outbreak of Exserohilum rostratum
meningitis illustrates the importance of access to rapid tests, with
diagnostics relying on the development of relevant PCR assays
[36] in addition to application of the β-D-glucan test [37] for
pathogen or biomarker detection in clinical specimens. Second,
despite the ability to develop diagnostic tests, probable and
possible IFD remain dependent on host criteria.
Almost 40% of patients had disseminated infection. In
particular, gastrointestinal tract, liver or eye involvement
should alert the clinician to look for other sites of infection. TheClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infburden of infection was also appreciable, with a 90-day mor-
tality of 44%. This underscores the need for validated, rapid
diagnostics to improve clinical outcomes [38]. Selection of early
and appropriate antifungal therapy is essential, as non-Aspergillus
moulds have variable antifungal susceptibilities [14,15,35].
Management of these infections was complex and prolonged.
Extended antifungal therapy, combined with surgery, was
required in 58.6% of patients, and 36% required ICU care. This
is pertinent, as ICU admission independently predicted mor-
tality, as did HM, rheumatological conditions, and disseminated
infection. Conversely, adjunctive surgery conferred a survival
advantage. Within fungal groups, we were unable to determine
independent predictors of mortality, owing to insufﬁcient pa-
tient numbers, except in patients with mucormycosis, where
predictors of death were similar to those for the whole patient
cohort. The overall all-cause mortality was similar to that found
in other series of diverse patient populations [2,3,15,19].
The study was limited by its retrospective nature, possible
ascertainment bias, and unexpectedly low numbers of probable
IFDs. The last of these may reﬂect the difﬁculty in diagnosing
probable (and probably true) infection in the absence of
accepted diagnostic criteria, or a lack of sufﬁcient diagnostic
effort. The diagnostic algorithms employed at the 15 contrib-
uting sites may have differed. Not all isolates underwent DNA
sequencing, so the occurrence of new/cryptic species was
probably underestimated, especially among Fusarium species
and the S. apiospermum/P. boydii species complex. The low
numbers of rare pathogens limits the ability to perform sub-
group analyses. As not all Australian jurisdictions provided data,
we cannot estimate the national burden of these infections.
In conclusion, this study provides contemporary information
about the spectrum of non-Aspergillus moulds causing IFDs and
the affected patient groups. Mortality remains high despite
aggressive antifungal therapy and surgery, although adjunctive
therapy was associated with a survival advantage. Early diagnosis
of these infections is needed to improve outcomes. Deﬁnitions
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